Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Inclusion Criteria: * Subject willing and able to give informed consent * Must be ≥19 and ≤45 years diagnosed with HPV infection in two tests within screening periods or have history of HPV infection within 6 months and diagnosed with HPV infection in one test within screening periods * No clinical abnormality from ECG test * Must agree to use appropriate contraceptive methods (ie, condoms, cervical cap in conjunction with spermicide, sterilization, and intra uterine device) during the study and for 3 months after the last dose of study drug. Exclusion Criteria: * Subject with HSIL or more severe HPV infection * History of a known or suspected hypersensitivity, shock, or past history to the investigational drug or to similar drugs * Malignant tumor within 5 years other than successfully treated skin cancer that is not melanoma * Active infection or history of infection that required intravenous injection of antibiotics 4 weeks prior to the first administration of the investigational drug * Female subject unwilling to stop breastfeeding or pregnancy * Positive result from serology examination for human immunodeficiency virus (HIV) * Major surgery within 3 months other than access surgery * Mental disorder or other central nervous system disorder determined that the study evaluation cannot be conducted * Participation in any clinical study within 30 days * History of alcohol or drug abuse within 6 months prior to the screening * Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study